首页> 外文期刊>Arzneimittel-Forschung: =Drug Research >Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i).
【24h】

Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i).

机译:2-(3,5-二叔丁基-4-羟苯基)-1,1-二膦酸四异丙酯(SR-9223i)的降胆固醇和抗动脉粥样硬化作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (CAS 126411-13-0, SR-9223i) is a member of a new class of compounds with multiple antiatherosclerotic activities. This report not only describes the cholesterol-lowering properties in four species of animals fed normocholesterolaemic diets but also reductions in lipid deposition in the arteries of cholesterol-fed New Zealand white rabbits following the administration of SR-9223i. Plasma cholesterol concentrations were reduced in mice by 27% (200 mg/kg/day administered in the diet for 10 days), in hamsters by 33% (200 mg/kg/day administered in the diet for 8 days), in dogs by 16% (25 mg/kg/day p.o. for 28 days) and 23% (75 mg/kg/day p.o. for 28 days) and in monkeys by 22% (25 mg/kg/day p.o. for 28 days). Further, the deposition of cholesterol, especially in the esterified form, in the aortae of cholesterol-fed New Zealand white rabbits was inhibited by SR-9223i (50 and 100 mg/kg/day p.o.). At the higher dose, the cholesteryl ester content of the aorta was half that of control animals. SR-9223i, at both doses, also inhibited the accumulation of cholesterol in the liver. SR-9223i has been shown to suppress HMG CoA reductase activity, inhibit ACAT activity and prevent lipid oxidation. These activities, demonstrated in vitro, have now been shown to translate into lipid lowering and antiatherosclerotic activities in vivo.
机译:2-(3,5-二叔丁基-4-羟基苯基)-1,1-二膦酸四异丙酯(CAS 126411-13-0,SR-9223i)是新型化合物的成员具有多种抗动脉粥样硬化活动。该报告不仅描述了饲喂降胆固醇饮食的四种动物的降低胆固醇的特性,而且还描​​述了在施用SR-9223i后胆固醇喂养的新西兰白兔动脉中脂质沉积的减少。小鼠血浆胆固醇浓度降低27%(饮食中每天200 mg / kg /天,持续10天);仓鼠血浆胆固醇浓度降低33%(饮食中每天200 mg / kg /天,持续8天);狗降低。在猴子中分别为16%(25 mg / kg /天,口服28天)和23%(75 mg / kg /天,口服28天),在猴子中则为22%(25 mg / kg /天,口服28天)。此外,SR-9223i(50和100 mg / kg / day p.o.)抑制了胆固醇喂养的新西兰白兔的主动脉中胆固醇的沉积,尤其是酯化形式的胆固醇的沉积。在较高剂量下,主动脉的胆固醇酯含量是对照动物的一半。两种剂量的SR-9223i均能抑制胆固醇在肝脏中的积累。 SR-9223i已显示出抑制HMG CoA还原酶活性,抑制ACAT活性并防止脂质氧化的作用。在体外证明了这些活性,现已证明在体内可转化为脂质降低和抗动脉粥样硬化活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号